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ABSTRACT: The 2-oxoglutarate (2OG)-dependent oxygenase JMJD6 is emerging as a potential anticancer target, but its
inhibitors have not been reported so far. In this study, we reported an in silico protocol to discover JMJD6 inhibitors targeting
the druggable 2OG-binding site. Following this protocol, one compound, which we named as WL12, was found to be able to
inhibit JMJD6 enzymatic activity and JMJD6-dependent cell proliferation. To our best knowledge, this is the first case in drug
discovery targeting JMJD6.
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Jumonji C (JmjC) domain-containing proteins belong to the2-oxoglutarate (2OG)-dependent oxygenase superfamily.
Most of them possess lysine demethylase (KDM) activity,1
while some were acknowledged as protein hydroxylases.2,3
Recently, several KDMs were also identified to be arginine
demethylases (RDM).4 The diverse enzymatic functions are all
executed by the JmjC domain that forms a catalytic site for
2OG-Fe (II) binding. Nowadays, the JmjC domain-containing
protein family has emerged as a new “star” in targeted-drug
discovery due to their diverse functions in human diseases,
particularly cancers. The enzymatic activity of JmjC domain-
containing proteins was often shown to be essential for its
function. Therefore, targeting the catalytic site was suggested
to be an effective way to interfere with their carcinogenic
function.5 For example, KDM5 inhibitor, EPT-103182, has
entered early preclinical study.6
JMJD6, the only arginine demethylase validated both in vitro
and in cultured cells,7 has been reported to be involved in
cancer development, including melanoma,8 colon cancer,9 lung
cancer,10 liver cancer,11 and breast cancer.12 Moreover, the
enzymatic activity of JMJD6 was found to be essential for its
function in cancer development. JMJD6 acts as a transcrip-
tional and splicing regulator through arginine demethylation or
lysine hydroxylation on both histones and nonhistone proteins.
Therefore, inhibiting the enzyme activity of JMJD6 is believed
to be a feasible solution for treatment of cancers where JMJD6
is involved. However, such inhibitors are yet to be discovered,
highlighting the urgency to develop new strategies for JMJD6-
targeted drug discovery.
In this study, the druggability of JMJD6 was first
computationally evaluated by elaborating the structure of the
JmjC domain of JMJD6. We then developed an in silico
protocol for virtual screening, aiming to rapidly discover small-
molecule inhibitors targeting the active site of JMJD6. The hit
compounds obtained by virtual screening were biologically
validated in terms of their inhibition on the demethylation
activity of JMJD6 and on the JMJD6-dependent cancer cell
proliferation. To our best knowledge, this is the first time to
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exploit the therapeutic potential of JMJD6 as anticancer target
through small-molecule inhibitor discovery.
Currently, most of the inhibitors targeting members in the
JmjC domain-containing protein family exert their inhibitory
activity by competing with 2OG binding, and they are defined
as 2OG-competitive inhibitors. We therefore tested the
druggability of the 2OG-binding site in JMJD6 by analyzing
the crystal structures (PDB IDs: 3k2o,14 3ldb,13 3ld8,13 6fqc)
of its JmjC domain. It is known that the JmjC domains share a
conserved double-stranded β-helix (DSBH) fold,15 which is
composed of central β sheets (β6∼β13) and peripheral α
helixes (α1∼α15) in JMJD6 protein (Figure 1A).16 The
central β sheets (amino acids 173 to 211 and 255 to 288 in
JMJD6) are responsible for binding with 2OG through shaping
a buried cavity (Figure 1B). The sequence of the JmjC domain
is highly similar between JMJD6 and other JmjC domain-
containing proteins (Figure S1). Histidine 187 (His187),
aspartic acid 189 (Asp189), and histidine 273 (His273) on the
β sheets form an iron-chelated catalytic triad to anchor 2OG,
which is highly conserved (Figure S1).17,18 Many other
residues are also involved in forming the 2OG-binding site
in JMJD6 (Figure 1B). Alignment of four independent crystal
structures of the JmjC domain complexed with different
ligands, such as 2-OG and NOG, gave small root-mean-square
deviations (RMSDs), suggesting that the JmjC domain of
JMJD6 is conformationally stable (Table S1). Stability of the
JmjC domain was further suggested by MD simulations of apo-
and holo-structures, which revealed a narrow RMSD window
from 1.0 to 3.0 Å relative to the crystal structures (Figure
S2A). RMSF of αC atoms demonstrated that the central β
sheets were especially stable than other regions (Figure S2B).
We then performed druggability analysis of JMJD6 by using
SiteMap19 and FTMAP20 methods. All crystal structures and
representative frames extracted from the MD trajectories based
on conformational clustering were used for the analysis.
SiteMap analysis showed that the 2OG-binding site was the
most likely druggable pocket due to its highest Dscore (Table
S2). Other structural characteristics were also acceptable as a
druggable pocket for the 2OG-binding site (Table S3). As
shown in Figure S3A, white dots representing the space
capable of grasping small-molecule ligands were distributed
consecutively from the core 2OG-binding region to the outer
regions near the L1 loop linking β3 and β4 and C-terminal
helixes (α13−α15). Hydrophobic regions that were important
for the binding of drug-like compounds were also distributed
consecutively in a large part of the cavity. Taken together, the
2OG-binding site might be a potential druggable pocket. The
pocket analysis by FTMAP, an alternative algorithm, was
consistent with the SiteMap outcome (Figure S4). It was worth
to note that SiteMap analysis revealed some other sites on the
protein surface as potential allosteric sites.21−23 However, these
sites had smaller Dscores than the 2OG-binding site (Table
S2) and significantly smaller volume than what is needed for a
druggable pocket, exemplified by the site formed by α1, α2,
and α6 helices that had the second highest Dscore (Figure S3B
and Table S4). Similar results were also obtained from the
AlloSite analysis (Figure S5).24
According to the analysis described above, the core 2OG-
binding region is superior to other regions in terms of
druggability, and virtual screening was carried out targeting this
region. To ensure the accuracy of our virtual screening, we
constructed a model based on protein−ligand interactions. As
JMJD6 inhibitors have not been reported yet, we docked the
scaffold moieties of the 2OG-competitive inhibitors targeting
other JmjC domain-containing proteins to JMJD6 to generate
protein−ligand interactions by the Glide docking method
(Figure 2A and Figure S6).25 The scaffolds were chosen for
pharmacophore generation as they were located at the core
2OG-binding region when binding with other JmjC domain-
containing proteins and were responsible for the coordination
interaction with iron ion (Figure S7).26−29 Thus, we
hypothesized that they could play a similar role in the binding
with JMJD6. As expected, all scaffolds were able to be chelated
with iron with at least one coordination interaction (Figure
2B). Meanwhile, more than one HB with Tyr131, Asn197, or
Lys204 was observed, which was shown to be important for
ligand binding in FTMAP analysis as described above.
Moreover, all scaffolds possessed aromatic rings located at
the hydrophobic regions around the iron ion identified by the
SiteMap analysis. These interaction features perfectly matched
the structural properties of the core 2OG-binding region of
JMJD6, indicating that ligands with similar interaction features
Figure 1. (A) Secondary structure of the JmjC domain in JMJD6
(3ldb).13 α helixes, β sheets, and loops were depicted in red, yellow,
and green, respectively. (B) Protein surface of the central β sheets
(3ldb).13 2OG, the catalytic triad residues and other representative
residues forming the 2OG-binding sites were depicted by magenta,
yellow, and blue sticks, respectively.
Figure 2. (A) Scaffold structures of known 2OG-competitive
inhibitors targeting other JmjC domain-containing proteins. (B)
Diagram for generating structure-based pharmacophore model.
Hydrogen-bonds (HBs) were shown as firebrick lines, and residues
were shown as green sticks (3ldb).13 H1 was a hydrophobic feature,
and A1 was an aromatic ring feature (right panel). HA1−HA3 were
hydrogen-bond acceptor features. Gray spheres represent EVS that
account for steric clashes of residues.
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to these scaffolds probably have the capability to bind to
JMJD6.
Next, the docking poses of the scaffolds were used for the
generation of interaction pharmacophore model with Li-
gandScout,30 which was a commonly used tool to extract
interaction features based on protein−ligand binding. The
pharmacophore features extracted from each JMJD6-scaffold
complex were clustered, which finally derived a pharmaco-
phore model with two HB acceptor features corresponding to
the coordination interaction with metal ion, one HB acceptor
feature projected to Lys204, one hydrophobic feature located
between the metal ion and Tyr131 or Phe133, and one
aromatic feature corresponding to Trp174 (Figure 2B). Among
these features, the coordination interaction with metal ion was
set as an essential feature in our virtual screening below, which
appeared in all 2OG-competitve inhibitors. These features
combined with excluding volume spheres (EVS) basically
covered the druggable regions as well as important interaction
sites revealed by the SiteMap and FTMAP analysis. This
pharmacophore model was subsequently applied to screen
several diversity and fragment libraries with a total of about 0.9
million compounds (see Supporting Information for details).
As a result, 7530 compounds passed the screening by the
pharmacophore model with the FitValues ranging from 0 to 4.
Among them, 5198 compounds were mapped to at least three
features. Moreover, most of them possessed the HA1 or HA2
features that corresponded to the coordination interaction with
metal ion. These compounds were further docked into the
2OG-binding site of JMJD6. On the basis of molecular
docking, 577 compounds were selected for further evaluation,
including the ones with better docking score than previously
used scaffolds, similar poses between the Glide docking and
pharmacophore mapping, or metal-chelated docking pose
identified by visual inspection. Most selected compounds had
acceptable drug-like properties (Figure S8). Considering
structural classification, pharmacophore mapping, docking
score, and drug-like properties, 12 non-PAINS31 and
purchasable compounds belonging to five types of scaffolds
were finally chosen for biological evaluation, which we named
WL1 to WL12 (Figure S9).
We then tested the activity of these compounds in inhibiting
JMJD6 demethylase activity by enzymatic assays. As shown in
Figure 3A, compounds WL1, WL2, WL8, WL9, WL10, WL11,
and WL12 inhibited the demethylase activity of JMJD6 as
examined by the demethylation assay followed by immuno-
blotting. Subsequently, we investigated the antiproliferation
effects of these compounds in HeLa and SMCC7721 cells in
which JMJD6 has been shown to play a vital role.11,32,33 It was
found that only WL12 exhibited antiproliferation effects. The
IC50 values for WL12 in HeLa and SMCC7721 cells were 2.44
and 10.18 μM, respectively (Figure 4B,C). Importantly, this
compound exhibited selectivity over normal cells, such as L02
hepatocyte cells (Figure S10). We then focused on
investigating the activity of compound WL12 in biochemical
assays and in cultured cells. First, the IC50 of WL12 targeting
JMJD6 was measured by demethylation assay (formaldehyde
release assay). It was found that the IC50 value was 0.22 μM,
which was highly reproducible (Figure 3D; Figure S11 and
Table S6). Moreover, WL12 exhibited selectivity over other
JmjC domain-containing proteins, such as PHF8/KDM7B,
JHDM2A/KDM3A, JMJD2C/KDM4C, and SMCX/KDM5C
(Figure S12). We then examined WL12 effects on JMJD6-
mediated demethylation in cultured cells. To this end, HeLa
cells were treated with or without WL12 followed by
immunoblotting to examine the levels of H4R3me2s as well
as HSP70R469me1, which is a nonhistone protein substrate we
reported previously.34 As expected, WL12 treatment led to a
significantly increase of HSP70R469me1, which was presum-
ably through inhibiting JMJD6 (Figure 3E). However, no
dramatic change of H4R3me2s was observed (Figure 3F),
Figure 3. (A) Demethylation assay was performed by mixing purified,
bacterially expressed JMJD6 with core histones in the presence or
absence of compound WL1 to WL12 (10 μM) followed by
immunoblotting with antibodies as indicated. H4R3me2s: histone
H4 arginine 3 symmetrical dimethylation. H4: histone H4. (B,C)
HeLa (B) and SMCC7721 (C) cells were treated with compound
WL12 at concentrations as indicated for 72 h followed by cell
proliferation assay. (D) Demethylation assay was performed by
mixing purified, bacterially expressed JMJD6 with core histones in the
presence or absence of compound WL12 at different concentrations
as indicated followed by formaldehyde release measurement. IC50 was
shown as indicated. The experiment was repeated three times, and
representative data was shown. The raw data and the IC50 for the
other two repeats were shown in Table S6 and Figure S10,
respectively. (E,F) HeLa cells were treated with or without WL12
(10 μM) for 6 h followed by immunoblotting assay using antibodies
as indicated. Molecular weight was indicated on the left. HSP70, heat
shock protein 70; HSP70 R469me1, HSP70 with monomethylated
arginine (R)-469.
Figure 4. Binding modes of compound WL7, WL10, and WL12 with
JMJD6. Residues interacting with ligands were shown by yellow sticks
(3ldb).13 The 2OG-binding site was shown as a yellow surface.
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which was consistent with our previous report that JMJD6
exhibits no global impact on histone methylation. Instead, it
functions only on specific gene loci.32 Finally, we demonstrated
that WL12 was able to bind with JMJD6 examined by Biacore
assay (Figure S13). Taken together, our structure-based virtual
screening was successful in discovering JMJD6 inhibitors for
future structural optimization.
We then examined the binding mode of WL12 with JMJD6
in more details. As shown in Figure 4, the docking pose of
WL12 occupied the core 2OG-binding region perfectly. The
coumarin and pyrazole rings both formed coordination
interactions with iron (Figure S13). The fused benzyl ring in
the coumarin group inserted into the inner pocket, forming an
σ−π interaction with Trp206. The pyridopyrazole ring made
an π−π stacking interaction with Trp174. These interaction
features well matched the pharmacophore model except that
the HB feature projected to Lys204 was missed. Compound
WL10 with the same coumarin scaffold as WL12 also made
π−π stacking with Trp174, but the stacking distance for WL10
was longer than WL12 (Figure S14). WL7, another analogue
of WL12, exhibited the opposite binding pose to WL12 so that
it hardly showed any activity against JMJD6. The binding
modes of WL7, WL10, and WL12 were also investigated by
MD simulations. The RMSDs indicated that JMJD6 was stable
when binding with WL12 (Figure S15A). The RMSDs for the
heavy atoms of WL12 were about 0.5 Å relative to the docking
pose (Figure S14B). The distance between iron and WL12 was
always maintained at a valid window from 2.0 to 2.3 Å for
coordination interaction (Figure S16).35 However, only the
coumarin−iron coordination interaction was maintained along
the simulation. The Trp174-mediated π−π stacking was
maintained along the simulation according to the distance
between the pyridine ring of WL12 and the indole ring of
Trp174 (Figure S15C). The simulations suggested that WL7
and WL10 were weaker than WL12 in terms of protein and
ligand flexibility (Figures S15A,B). The structure of the
catalytic triad was even deformed when the two compounds
were bound (Figure S16).
In conclusion, our analysis revealed that the 2OG-binding
site of JMJD6 is a druggable pocket for ligand binding.
Following our virtual screening protocol, several small-
molecule inhibitors capable of inhibiting JMJD6 demethylase
activity in vitro were discovered. Among them, inhibitor WL12
was shown to be able to suppress JMJD6-dependent cancer cell
proliferation including cervical and liver cancer cells, providing
a small-molecule probe for studying the biological functions of
JMJD6 in cancer development. We envision that a campaign
seeking JMJD6 inhibitors to treat cancers will begin following
our study.
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